查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1634205

全球神经血管设备市场 - 2025 - 2033

Global Neurovascular Devices Market - 2025 - 2033
出版日期: | 出版商: DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年，全球神经血管器械市场规模达38亿美元，预计2033年将达84亿美元，2025-2033年预测期间复合年增长率为9.4%。

神经血管设备是一种专门的医疗器械，旨在治疗影响大脑和脊髓血管的疾病。这些设备主要用于与神经介入相关的手术，神经介入是介入放射学、神经病学和神经外科的一个分支，专注于诊断和治疗各种神经血管疾病的微创技术。

神经血管装置的主要目的是利用微创技术恢復血流、阻塞或移除异常血管，并预防或治疗危及生命的疾病，如中风、脑出血和动脉瘤。这些设备旨在透过减少恢復时间、併发症和传统开放性手术的需要来改善患者的治疗效果。

在神经血管疾病日益流行和神经血管设备技术进步的推动下，神经血管设备市场正在经历显着增长。中风、脑动脉瘤和动静脉畸形等疾病变得越来越常见，增加了对神经血管设备的需求。

例如，根据世界中风组织的数据，每年有超过 760 万例新缺血性中风。在全球范围内，超过 62% 的中风是缺血性中风。每年，超过 11% 的缺血性中风发生在 15-49 岁的人群中。每年，超过 58% 的缺血性中风发生在 70 岁以下的人群中。

此外，2024 年5 月，Penumbra, Inc. 宣布获得CE 标誌批准，并在欧洲推出其三款神经血管再灌注导管Red 43、采用SendIt 技术的Red 72 和Red 78，用于治疗急性缺血性中风。据 Penumbra 称，这些设备优化了基于科学的血栓抽吸术（S-BAT），并采用最新的可追踪性和抽吸技术进行设计，以解决各种大血管闭塞问题。

市场动态：

驱动程式和限制

神经血管设备不断进步的技术

神经血管设备不断进步的技术进步极大地推动了神经血管设备市场的成长，预计将在预测期内推动市场的成长。较新的神经血管装置，例如分流器、支架回收器和栓塞线圈，其设计侵入性较小，可减少患者的恢復时间和併发症。例如，2024年8月，重力医疗科技推出了下一代中风治疗设备：Neutron抽吸导管和Supernova支架取回器。早期采用已成功治疗全球 60 多名患者。

此外，2024年6月，Terumo子公司MicroVention在美国推出了用于治疗宽颈颅内动脉瘤的LVIS EVO腔内支撑装置。毫米或5毫米的囊状颅内动脉瘤。

该设备现在与增强的 2D 和 3D 成像技术集成，提供即时可视化来指导手术。此技术可帮助神经外科医师更精确地放置设备，确保更安全、更有效的治疗。

例如，2024 年 2 月，皇家飞利浦宣布对其影像导引治疗系统 Azurion 进行重大改进，推出新型 Azurion 神经双翼系统。新型介入系统旨在提高工作效率并帮助护理团队更快地做出正确决策、治疗更多患者并取得更好的结果，具有增强的 2D 和 3D 成像以及 X 射线探测器定位灵活性。新的影像导引治疗系统是一个完整的介入解决方案，可为中风或其他神经血管疾病患者提供可靠的诊断、影像导引和治疗评估

替代方案的可用性

替代治疗方案的可用性是阻碍神经血管设备市场成长的关键因素之一。存在多种基于设备的干预措施的替代方案，并且在许多情况下，由于成本效益、患者偏好和治疗的侵入性较小等因素，这些替代方案是首选。

许多神经血管疾病，例如缺血性中风或脑动脉瘤，可以使用药物而不是介入设备进行治疗。抗血小板药物（例如阿斯匹灵）和抗凝血剂（例如华法林、利伐沙班）等药物治疗可以预防血栓形成并降低中风或动脉瘤破裂的风险。例如，使用溶栓剂（例如组织纤溶酶原激活剂，tPA）治疗急性缺血性中风通常可以减少对血栓切除术或其他基于设备的干预措施的需求，从而限制对神经血管设备的需求。

在某些情况下，传统的开放性手术仍然是首选，特别是对于复杂或大型动脉瘤和动静脉畸形（AVM）。儘管开放式手术不如微创方法常用，但它可以被视为一种更成熟、更可靠的选择。例如，对于患有巨大或难以治疗的脑动脉瘤的患者，可能会建议进行夹闭手术，而不是栓塞或血流改道，这会减少神经血管装置的市场份额。

有时，立体定位放射手术或雷射消融等替代方法是治疗脑肿瘤、动静脉畸形和其他血管病变的首选方法。与传统的神经血管手术相比，这些方法风险较低，侵入性也较小。例如，伽玛刀放射外科手术经常用作动静脉畸形栓塞或手术切除的替代方法，特别是对于小病变。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分類的片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 神经血管设备不断进步的技术
    • 限制
      • 替代方案的可用性
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和主要创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：神经血管设备市场，依产品类型

  • 脑栓塞及动脉瘤弹簧圈装置
    • 栓塞弹簧圈
    • 分流装置
    • 液态栓塞剂
  • 脑血管成形术和支架系统
    • 颈动脉支架
    • 栓塞保护系统
  • 神经血栓切除装置
    • 血块回收装置
    • 抽吸装置/抽吸导管
    • 血管圈套器
  • 支援设备
    • 微导管
    • 微型导丝
  • 跨径向接入设备

第 6 章：神经血管设备市场（依应用）

  • 脑动脉瘤
  • 缺血性中风
  • 颈动脉狭窄
  • 其他的

第 7 章：神经血管设备市场（依最终用户）

  • 医院
  • 专科诊所
  • 手术中心
  • 研究实验室和学术机构
  • 门诊手术中心

第 8 章：神经血管设备市场，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 9 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 10 章：公司简介

  • Medtronic plc
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • Stryker Corporation
  • Terumo Corporation
  • MicroPort Scientific Corporation
  • Johnson & Johnson
  • Penumbra, Inc.
  • ASAHI INTECC USA, INC.
  • Acandis GmbH
  • Rapid Medical
  • NeuroVasc Technologies, Inc.

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD2674

The global neurovascular devices market reached US$ 3.8 billion in 2023 and is expected to reach US$ 8.4 billion by 2033, growing at a CAGR of 9.4% during the forecast period 2025-2033.

Neurovascular devices are specialized medical instruments designed to treat conditions affecting the blood vessels of the brain and spinal cord. These devices are primarily used in procedures related to neurointervention, a branch of interventional radiology, neurology and neurosurgery, which focuses on minimally invasive techniques for diagnosing and treating various neurovascular diseases.

The main purpose of neurovascular devices is to restore blood flow, block or remove abnormal blood vessels, and prevent or treat life-threatening conditions like strokes, brain hemorrhages and aneurysms, using minimally invasive techniques. These devices aim to improve patient outcomes by reducing recovery time, complications, and the need for traditional open surgeries.

The neurovascular devices market is experiencing significant growth, driven by the increasing prevalence of neurovascular disorders and technological advancements in neurovascular devices. Conditions such as stroke, cerebral aneurysms, and arteriovenous malformations are becoming more common, increasing the demand for neurovascular devices.

For instance, according to the World Stroke Organization, there are over 7.6 million new ischaemic strokes each year. Globally, over 62% of all incident strokes are ischaemic strokes. Each year, over 11% of all ischaemic strokes occur in people 15-49 years of age. Each year, over 58% of all ischaemic strokes occur in people under 70 years of age.

Additionally, in May 2024, Penumbra, Inc. announced the CE Mark approval and the launch in Europe of three of its neurovascular reperfusion catheters Red 43, Red 72 with SendIt technology, and Red 78 for the treatment of acute ischemic stroke. According to Penumbra, the devices optimize science-based aspiration thrombectomy, or S-BAT, and are engineered with the latest technology in trackability and aspiration to address a wide range of large vessel occlusions.

Market Dynamics: Drivers & Restraints

Rising technological advancements in neurovascular devices

The rising technological advancements in neurovascular devices are significantly driving the growth of the neurovascular devices market and are expected to drive the market over the forecast period. Newer neurovascular devices, such as flow diverters, stent retrievers and embolic coils, are designed to be less invasive, reducing recovery times and complications for patients. For instance, in August 2024, Gravity Medical Technology launched its next-generation stroke treatment devices: the Neutron aspiration catheter and the Supernova stent retriever. Early adoption has demonstrated the successful treatment of more than 60 patients worldwide.

Additionally, in June 2024, Terumo subsidiary MicroVention launched its LVIS EVO intraluminal support device to treat wide neck intracranial aneurysms in the U.S. The device is indicated for usage with neurovascular embolization coils in adults to treat saccular intracranial aneurysms with a neck width of 4 mm or greater or a dome-to-neck ratio of less than two that arise from a parent vessel with a diameter between 2 and 4.5 mm.

Devices now integrate with enhanced 2D and 3D imaging technologies, providing real-time visualization to guide procedures. This technology helps neurosurgeons place devices more precisely, ensuring safer and more effective treatments.

For instance, in February 2024, Royal Philips announced major enhancements to its Image Guided Therapy System, Azurion, with the launch of its new Azurion neuro biplane system. Designed to improve productivity and help care teams make the right decisions faster, treat more patients, and achieve better outcomes, the new interventional system features enhanced 2D and 3D imaging and X-ray detector positioning flexibility. The new image-guided therapy system is a complete interventional solution for confident diagnosis, image guidance, and therapy assessment of patients with stroke or other neurovascular diseases

Availability of alternatives

The availability of alternative treatment options is one of the key factors that can hamper the growth of the neurovascular devices market. Several alternatives to device-based interventions exist, and in many cases, these alternatives are preferred due to factors such as cost-effectiveness, patient preference and the less invasive nature of the treatments.

Many neurovascular disorders, such as ischemic stroke or cerebral aneurysms, can be treated using medications rather than interventional devices. Pharmacological treatments like antiplatelet drugs (e.g., aspirin) and anticoagulants (e.g., warfarin, rivaroxaban) can prevent clot formation and reduce the risk of stroke or aneurysm rupture. For instance, the use of thrombolytics (e.g., tissue plasminogen activator, tPA) for acute ischemic stroke can often reduce the need for thrombectomy or other device-based interventions, thus limiting demand for neurovascular devices.

In some situations, traditional open surgery remains the preferred option, especially for complex or large aneurysms and arteriovenous malformations (AVMs). Although less commonly used than minimally invasive methods, open surgery can be seen as a more established and reliable option. For instance, for patients with large or difficult-to-treat brain aneurysms, clipping surgery may be recommended over embolization or flow diversion, which can reduce the market share of neurovascular devices.

Alternatives like stereotactic radiosurgery or laser ablation are sometimes preferred for treating brain tumors, arteriovenous malformations, and other vascular lesions. These methods can offer less risk and are less invasive than traditional neurovascular procedures. For instance, Gamma Knife radiosurgery is frequently used as an alternative to embolization or surgical resection for AVMs, particularly for small lesions.

Segment Analysis

The global neurovascular devices market is segmented based on product type, application, end-user and region.

Product Type:

The cerebral angioplasty and stenting systems segment is expected to dominate the neurovascular devices market share

Over the years, technological advancements in angioplasty and stenting systems have improved treatment efficacy, safety and patient outcomes. The development of self-expanding stents, drug-eluting stents and balloon angioplasty systems has enhanced the precision and success rates of neurovascular procedures.

For instance, in June 2023, Fluid Biomed Inc. announced the World's first implantation of a polymer-based neurovascular stent in human patients, REDIRECT, its first-in-human clinical trial. Phase 1 of this technical feasibility and safety study has begun with successful device implantation without adverse effects in human subjects at the pre-determined 30-day time point and recruitment is ongoing.

Cerebral angioplasty and stenting are minimally invasive procedures, which are preferred by both patients and physicians because they involve smaller incisions, reduced recovery times, and fewer complications compared to traditional open surgeries. For instance, Angioplasty with stenting for carotid artery disease is performed through a small incision in the groin, making it a less traumatic alternative to surgery. This less invasive nature drives higher adoption of stenting systems in treating neurovascular diseases.

Endovascular treatments, such as cerebral angioplasty and stenting, are increasingly becoming the first line of treatment for neurovascular disorders due to their effectiveness and reduced risks compared to open surgery. This shift in preference is contributing to the dominance of the segment.

Geographical Analysis

North America is expected to hold a significant position in the neurovascular devices market share

North America especially the United States, is a hub for innovation in medical devices, with leading companies such as Medtronic, Stryker Corporation, Terumo Corporation and other leading players developing new and improved neurovascular devices. This includes the development of stent retrievers, flow diverters and clot removal devices that are highly effective in treating stroke and aneurysms.

For instance, in February 2024, CERENOVUS, Inc., part of Johnson & Johnson MedTech, launched CEREGLIDE 71 Intermediate Catheter, a next-generation intermediate catheter with TruCourse indicated for the revascularization of patients suffering from acute ischemic stroke. CEREGLIDE 71 Intermediate Catheter is the latest innovation in a planned CEREGLIDE Family of Catheters to join the CERENOVUS STROKE SOLUTIONS portfolio and is optimized for effective direct aspiration and for the delivery of compatible stent retrievers, including the EMBOTRAP III Revascularization Device, into the neurovasculature.

Asia-Pacific is growing at the fastest pace in the neurovascular devices market

The Asia Pacific region has a growing incidence of stroke, aneurysms, and carotid artery diseases due to lifestyle factors, rising levels of hypertension, smoking, and diabetes, which are risk factors for neurovascular conditions. For instance, the World Health Organization (WHO) reports that Asia, particularly China and India, has a high incidence of ischemic stroke, with nearly 70% of all strokes occurring in low- and middle-income countries in Asia. This significantly boosts the demand for neurovascular devices such as stents, coils, and thrombectomy systems.

There is an increasing awareness of minimally invasive neurovascular procedures such as stenting, angioplasty, and thrombectomy in the Asia Pacific region. As healthcare professionals and patients become more informed about the benefits of these procedures, the demand for neurovascular devices increases. For instance, the use of thrombectomy systems like the Solitaire FR Stent Retriever is growing in countries like India and China as part of the initiative to improve stroke treatment outcomes.

Competitive Landscape

The major global players in the neurovascular devices market include Medtronic plc, Stryker Corporation, Terumo Corporation, MicroPort Scientific Corporation, Johnson & Johnson, Penumbra, Inc., ASAHI INTECC USA, INC., Acandis GmbH, Rapid Medical, NeuroVasc Technologies, Inc. and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global neurovascular devices market report delivers a detailed analysis with 62 key tables, more than 57 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Technological Advancements in Neurovascular Devices
    • 3.1.2. Restraints
      • 3.1.2.1. Availability of Alternatives
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Neurovascular Devices Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Cerebral Embolization and Aneurysm Coiling Devices*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Embolic Coils
    • 5.2.4. Flow Diversion Devices
    • 5.2.5. Liquid Embolic Agents
  • 5.3. Cerebral Angioplasty and Stenting Systems
    • 5.3.1. Carotid Artery Stents
    • 5.3.2. Embolic Protection Systems
  • 5.4. Neurothrombectomy Devices
    • 5.4.1. Clot Retrieval Devices
    • 5.4.2. Suction Devices/Aspiration Catheters
    • 5.4.3. Vascular Snares
  • 5.5. Support Devices
    • 5.5.1. Micro Catheters
    • 5.5.2. Micro Guidewires
  • 5.6. Trans Radial Access Devices

6. Neurovascular Devices Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Cerebral Aneurysms*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Ischemic Stroke
  • 6.4. Carotid Artery Stenosis
  • 6.5. Others

7. Neurovascular Devices Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Surgical Centers
  • 7.5. Research Laboratories and Academic Institutes
  • 7.6. Ambulatory Surgical Centers

8. Neurovascular Devices Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Medtronic plc*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Stryker Corporation
  • 10.3. Terumo Corporation
  • 10.4. MicroPort Scientific Corporation
  • 10.5. Johnson & Johnson
  • 10.6. Penumbra, Inc.
  • 10.7. ASAHI INTECC USA, INC.
  • 10.8. Acandis GmbH
  • 10.9. Rapid Medical
  • 10.10. NeuroVasc Technologies, Inc.

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us